Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great buy on Thursday or Friday
Anyone buying dogecoin on the pullback?
Not a bad entry level.
What scanning system people using, and what are you looking for in your trade? Technicals?
You guys trade this or TZA and TNA?
Broke my rule on BMY and cut a 2.25% loss sold at 49.61 this morning from 50.75 entry. Never hold through any Data.
$BMY ASCO Abstracts and PR. Have an average price of $50.75 and plan on holding until moving averages change my mind (see chart from other post). Like what I hear and see. Even though down slightly in AH
http://www.nasdaq.com/press-release/investigational-pd1-immune-checkpoint-inhibitor-nivolumab-receives-us-fda-breakthrough-therapy-20140514-01286
http://www.nasdaq.com/press-release/investigational-pd1-immune-checkpoint-inhibitor-nivolumab-showed-antitumor-activity-in-previously-20140514-01292
http://www.nasdaq.com/press-release/bristolmyers-squibb-announces-two-and-threeyear-survival-data-for-nivolumab-an-investigational-pd1-20140514-01314
http://www.nasdaq.com/press-release/in-phase-2-and-1b-renal-cell-carcinoma-trials-investigational-pd1-immune-checkpoint-inhibitor-20140514-01331
[/URL]" rel="nofollow" target="_blank" >insert-text-here
BMY Abstracts for ASCO released Wed. 5pm Will be a lot of focus on PD-1 targeting therapy's. Nivolumab being one of them. Interested to see what happens, not sure if will hold or not (most likely will) seeing how the stock reacts next week. Macd about to cross signal line, Macd hista moving up, momentum over 100, 3&5SMA heading up with 3 over 5, price > 10&20SMA. It has held up well for all the bio drama.
Last ASCO we had a 17% run in 18 days.
[/URL]" rel="nofollow" target="_blank" >insert-text-here
BMY Chart was looking for a ASCO trade and this is the only one out of 14 on my scan list that is setting buy signals. Also has a PDUFA date of 8/25/2014. Entered at 50.75 hoping we brake out and not bounce down.
Presenting at ASCO
http://finance.yahoo.com/news/bristol-myers-squibb-continues-lead-113000473.html
[/URL]" rel="nofollow" target="_blank" >insert-text-here
IBB Chart next few days will be interesting, earnings coming out for some biotechs this week. New side ways channel or do we brake back up? Would like to see touch BBB again and see trade in a nice channel, more trades like that.
[/URL]" rel="nofollow" target="_blank" >insert-text-here
Exited KERX today at 14.46 from 14.05 based on short term moving avg. Didn't like the way it was trading, thinking market waiting on financials, which I would think would be decent. They sold almost 7mil shares at $14.5 in Jan and trails expenses should be down. May look to reenter.
Looking for ASCO play right now.
Kerx chart, Only stock holding as of now, entered yesterday at $14.05 based on short term moving averages, RSI, and etc...
[/URL]" rel="nofollow" target="_blank" >insert-text-here
Been gone for awhile (years). Had Some financial issues I had to handle and etc... Unfortunately I am back with only a $3,400 account but God has been good and always is. Time to get back in business and love this board, something about Sheff and his humbleness and wanting to help children in need that made me want to come back and trade with the people here. Hope all has been well. God bless
Stock charts to watch for uptrend.
LGND,CORT,VRX,OSIR,ARIA,BLRX,ALNY,XNPT
Read up on the H7N9 and read this article. I think in a couple weeks we may get news of sinovac and the vaccine. All speculation
http://www.ecns.cn/2013/04-19/59741.shtml
The H7N7 thing is heating up. 5 more people infected and may be spreading from human to human. This stock shot to 12 dollars in 2009 for swine flu pandemic. This is a per speculative buy but could pay off nice if china request a vaccine.
POZN in here for longer term recovery.
Got crushed on SVA today, still holding to try and get my money back at least. Do your own DD, this is reasons why I am holding.
Already dropped past my stop and don't like being down this much so hoping to recover.
If this ends up being true I believe Sinovac will be the ones getting the a deal.
http://www.theatlanticwire.com/global/2013/04/china-bird-flu-human-to-human/64339/
http://www.bloomberg.com/news/2013-04-15/bird-flu-surge-in-china-spurs-h7n9-pandemic-vaccine-preparations.html?cmpid=yhoo
What bears think
http://www.fool.com/investing/general/2013/04/18/why-sinovac-is-poised-to-keep-pulling-back.aspx
(In addition, yesterday, Dr. Zhu Fengcai, Deputy Director of the Jiangsu Provincial Center for Disease Control and who is the co-principal investigator of our Phase III trial, presented additional efficacy and safety data from the trial that was conducted in Jiangsu Province. On the 13th Annual World Vaccine Congress and Expo held in Washington DC, of the United States. And this data shows that EV71 vaccine has 95% efficacy, when compared to the placebo group, and safety was comparable, between the vaccine group and placebo group, and injection site and general adverse reaction was similar across both groups. We are working with the PR team to drop an article about this vaccine for a (inaudible) journal and we will make an announcement on the publish of this article, once it's completed.
Our clinical research and regulatory team are right now working on the summary reports of the clinical studies and also to prepare the new drug application dossier, and we expect to submit the application for the new drug license to China's FDA by the end of May.
Bird Flu H7 and H9
Our next question comes from the line of Yi Chen with Aegis Capital. Please proceed with your question.
Yi Chen - Aegis Capital
Hi. Thank you for taking my questions. My first question is, what is Chinese government's current opinion on whether it is necessary to develop that same for H7 and H9?
Weidong Yin - Chief Executive Officer
[Foreign Language].
Helen Yang - Investor Relations Manager
To translate Mr. Yin's answer to that question, actually Sinovac was engaged in developing vaccines against the potential pandemic of flu kind of viruses, starting from 2004, at the time, we were developing H5N1 vaccine. But after that many years, we actually -- we didn't obtain too much profit or revenues from these products, but we think we actually gathered the platforms, and people were trained to do that. By the year of 2009 and 2010, H1N1 caused a very serious pandemic, and Sinovac also led a research to develop a vaccine, and that actually gave the company a good opportunity, in terms of selling the vaccine and also to provide a vaccine stockpile by the government, and now, there is new viruses, also within the flu family, the H7 and H9 epidemic, that actually provides the possibility for Sinovac to do the research on another kinds of avian flu vaccines for humans.
.
Weidong Yin - Chief Executive Officer
[Foreign Language].
Helen Yang - Investor Relations Manager
As you remember that, actually in last year, we have completed our GMP certification for our new -- brand new filling and packaging line on our new site, and also our flu (inaudible) certification, GMP certification was completed as well, and we believe that Sinovac has the capability technically to develop a new type of avian flu vaccine for humans. However, there are big uncertainties of the epidemic situation, and whether this virus will come up through human-to-human transmission, and maybe some of you have seen that the company has explained to the media that once we obtain overseas from either the (inaudible), we will immediately start to do the development of the vaccine, and this partly is that we want to be a responsible company for the social society and also we think that even though there are some uncertainties, but we would like to be ready, once there is any good opportunities for us, and we would expect that our shareholders and our friends could be closely monitoring the situation with us, on how this epidemic would be developed in the next few months.
The reason their earnings was less
(2011 sales included recognition of approximately $14 million revenue from Panflu and Panflu.1 vaccines, stockpiled by the Chinese government in 2010. These two products are not for regular sales, since they were produced upon government order and subject to the government decision of using the vaccines within its shelf life, if there was any flu pandemic caused by H1N1 and/or H5N1. The company's revenue recognition requirements were not met until the fourth quarter of 2011; and in 2012, there was no revenue recognized for either Panflu or Panflu.1.
Compared with the fourth quarter of 2011, the gross profit margin for the fourth quarter of 2012 decreased from 62% to 54.1%. The high gross margin in the fourth quarter of 2011 was due to the recognition of $14 million in revenue from H1N1 vaccine stockpiling, which has higher gross margin than the other vaccines.)
http://seekingalpha.com/article/1351461-sinovac-biotech-s-ceo-discusses-f4q2012-results-earnings-call-transcript?page=5&p=qanda&l=last
SVA Watch this morning. I got in yesterday, we had an end of day sell off which I believe was investors getting out before 4th quarter financial report this morning. I think SVA may surprise investors with earnings and will add more fuel to it's bird flu fire. I could be wrong but the reason I think they had a good fourth quarter is below.
Do your dd on this one, but if China wants
http://www.marketwatch.com/story/sinovac-receives-beijing-cdc-tender-award-to-supply-seasonal-flu-vaccine-anflur-to-beijing-citizens-2012-09-10
http://www.marketwatch.com/story/sinovac-awarded-tenders-in-beijing-and-shanghai-to-supply-inactivated-hepatitis-a-vaccine-healive-under-expanded-immunization-program-2012-09-25
A surge in bird flu cases in China increases the pandemic potential of the H7N9 strain, according to a Beijing-based supplier of influenza vaccines to the Chinese government.Sinovac Biotech Ltd. (SVA), the first company to win regulatory approval for a swine flu shot in 2009, is preparing to make immunizations against the new virus. The Nasdaq-traded company will hold off producing the shots until it’s received an order from the state, said Chief Executive Officer Yin Weidong.“The risk of this becoming a pandemic is increasing,” Yin said in an interview at the company’s headquarters in the Chinese capital, where a second H7N9 infection was reported today.Sinovac has notified its suppliers that it may need to order additional fertilized chicken eggs to produce H7N9 vaccine, Yin said.Under an agreement with China’s Food and Drug Administration, a Sinovac vaccine for pandemic flu doesn’t need to undergo clinical testing because its production methods have already been approved and the pandemic flu vaccinewould represent only a change in the viral strain, he said.
http://www.bloomberg.com/news/2013-04-15/symptom-free-bird-flu-case-suggests-wider-h7n9-spread.html
ALKS wanted to enter this morning when it was up 10% but didn't. Has been moving since.
SVA maybe a better play for it Clem. Just thought I would share. Lunch time drop would have been a good entry.
http://www.bloomberg.com/news/2013-04-15/bird-flu-surge-in-china-spurs-h7n9-pandemic-vaccine-preparations.html
SVA buying here. China flu news and deaths increasing. I believe the CDC in China picked SVA for their flu vaccine in 2011. Could touch 5 I hope.
Sheff I feel like hitting my head for not holding this longer. Put my sell in before it opened at market, because I did not think I would have much time to watch it on my Scottrade account. Left a possible 13% on the table. Oh well taking profit I guess is what matters when trading.
Friday post
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=86776696]
Todays post
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=86840885
thoughts and prayers go out to those in Boston.
THRX out with 7 percent profit from Friday entry. Hope goes well Wed but locked in profit at 25.35 from 23.63 Should have held longer
THRX. notes are out look over them. Hoping for a positive vote on Wed. Got in at 23.63 on Friday see previous post. Do your dad first don't have time to post any sorry.
IMGN Glad I took my profit. I guess that's why its good to never fall in love with a stock.
THRX. just entered for Monday panel notes. Sheff check this one out could be good trade for Monday
CNDO small market cap and moving on offering at market value.
IMGN strong close. Took profit from 15.3 and 15.5 entry will look to re enter in about a month. Hope I don't miss the boat.
KERX Broke tight bollingbands to the up side
Agreed. I think everyone will be looking at the panel first
DCTH. as long as the reason I was holding has not changed no reason to panic trade.
Dr frost as an insider has been buying a lot of OPK
Thanks sheff I think I am going to try and trade it wisely keeping a close eye on it. My portfolio balance is just to small to hold for years. Need to be locking in profit and moving. Thanks again
Sheff have you ever liked a stock long enough to hold for years? I am feeling that way now about IMGN. But for right now short term they have an investor conference the 12th, IMGN901 sclc interim data should be in august (6 months after their full enrollment.) And phase 3 data for TDM-1 first line should be year end. Doctors seem to love this drug and I posted an article yesterday how it was being used for another cancer in a guys intestines. I think earnings will surprise some people even though they receive a small royalty percentage. When approved for first line could generate a nice yearly income (around 300 mil for IMGN). From what I am seeing and hearing I really doubt it would not be the best first line treatment on the market once approved. I would hope the FDA moves quick as possible on it considering the benefits to patients.
I always told myself never to fall in love with a stock, but feel like in 5 years this stock could be sitting nicely if not bought out. I want to just trade it but would hate it to take off and not look back when I am out. I traded before approval and after approval but now I am actually thinking about holding and adding to my position with other profits. Whats your thoughts? Thanks
ENDP. has been moving and panel in may
TDM1 being used in other cancers already. Speaking of cancer stocks IMGN I think will have a good year. Stopped out on cldx but no stops on IMGN.
Thought this was good too know and interesting. The hospital charged way more then genentech though
Since the diagnosis, his cancer has been controlled by various medications that attacked his cancer cells and healthy cells alike. As a result, he has been struggling with fatigue, loss of hair, and swelling of his leg.But a promising new drug recently approved by the Food and Drug Administration appears to be the solution for treating Bennett's cancer without the debilitating symptoms that makes him feel “sick as a dog,” he said.
Bennett's HER-2 positive cancer is Ampullary adenocarcinoma, targeting his biliary tract, the common anatomical term for the path by which bile is secreted by the liver then transported to the first part of the small intestine.
http://www.fosters.com/apps/pbcs.dll/article?AID=/20130404/GJNEWS_01/130409668/-1/rocnews
Doctors seem to love it
http://www.google.com/search?redir_esc=&redir_esc=&hl=en&source=android-browser-type&v=200400000&qsubts=1365156372668&q=tdm1%20doctor
Even with small royalty percentage once approved for first line could bring in a lot of revenue for IMGN. I think earnings for what it is approved for now will be a surprise.
Interim data for IMGN901 SCLC is about 4 months away with a lot of other stuff in the workks.
Would watch today was mentioned on mad money last night may try and take profits and reentrer if spikes. Made money on this stock on approval run up sand approval. Think I am now long.
ImmunogenCramer said Immunogen [ IMGN 15.54 +0.40 (+2.64%) ]develops a unique kind of cancer treatments – something called targeted antibody payload technology."Basically, Immunogen's drugs use antibodies to hunt down cancer cells—like a guided missile—and then they hit the cancer with a highly-toxic payload that's anywhere from a hundred to a thousand times more potent than traditional chemotherapy," Cramer said.The company achieved a milestone back in February when the FDA approved Kadcyl , a breast cancer drug that has the potential to be a major blockbuster."It has the potential to generate $6.7 billion in peak sales by 2020 if it gets all the additional approvals needed," said Cramer.However, this drug was developed in partnership with Roche, [ ROG-CH 221.60 +0.10 (+0.05%) ] and that deal cuts into Immunogen's profits. But, perhaps more important, Cramer said the FDA approval validates Immunogen's technology."That's important because this company has a near-term pipeline full of drugs that it actually owns outright, unlike Kadcyla. They have a small cell lung cancer treatment that we should get phase 2 data on in the second half of the year—potentially a billion dollar opportunity."Also Cramer thinks the downstream pipeline looks promising, too. "Immunogen has some early stage drugs: one for lung and ovarian cancer, one for Lymphoma, one for head and neck cancer, of course, all of these will remain in trials for years before they're ready to be submitted to the FDA."
http://m.cnbc.com//id/100617774
Cramer said shares of ImmunoGen have doubled since he first recommended it in November 2009, but this $1.3 billion company still has a lot of room to run. The company's targeted cancer therapies are far more potent than old-line treatments.While recent drug approvals may benefit ImmunoGen's many partners more than itself, Cramer said the approvals validate the technology and will translate into big wins for the company's many other drugs in its pipeline. He advised waiting for a pullback in the stock before buying in ahead of its April 12 analyst day.http://www.thestreet.mobi/story/11888150/1/cramers-mad-money-recap-economists-dont-know-stocks.html
Has a lot going on in this year and the future. Also keeping an eye on SGEN.
POZN keep an eye on this one, oversold. Has been upgraded by multiple funds and downgraded by the street. Could be a good buying opportunity. Has not been this low in awhile.
Any word on IMUC has dropped. 40 in the last couple trading session.
ITMN chart look to be heading upward. Don't have time to post pics sorry.